 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] According to the pharmaceutical industry on the 5th, according to the results of phase 1 and 2 clinical trials of candidates for dry eye treatment (YP-P10) released by Yuyu Pharmaceutical on the 2nd of this month, there was no statistically significant difference in the total corneal color index (TCSS) and eye discomfort (ODS) compared to placebo (fake medicine).
However, in the summer test (Schirmer test· tear secretion test), one of the secondary evaluation indicators, the amount of tear secretion increased just 15 days after administration, showing a significant improvement effect. Yuyu Pharmaceutical plans to establish R&D (R&D) direction in the future after the first analysis.
Earlier on the 19th of last month, HL036, a candidate substance for dry eye treatment jointly developed by Daewoong Pharmaceutical Co. and Hanol BioPharma Co., failed to prove its effectiveness in the second U.S. clinical third phase. This treatment is a biopharmaceutical that prevents corneal damage by suppressing the activity of TNF (oncological necrosis factor) that causes inflammation in the body.
In the Shermer test, the second evaluation index, the candidate material also showed statistically significant results compared to the placebo, but the remaining two surveys did not produce meaningful results. The candidate material has not been confirmed to be effective in Chinese clinical trials last year and is under further clinical review. However, Hanol Biopharma plans to redesign the clinical trial and re-challenge the third phase of the US market.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
